HEOR publications

Journal Articles


31. Vogelzang NJ, Hackshaw MD, Hutson TE, Bhowmik D, Yap M, Rembert D, Jonasch E. First-line and sequential use of pazopanib followed by mammalian target of rapamycin inhibitor


Conference abstracts


69. Boyd M, Annavarapu S, Doshi GK, Imai K, Shab E, Godwin JL, Li H, Sonpavde G. Real-world outcomes of metastatic urothelial carcinoma (mUC) patients (pts) treated with first or second-line immunotherapies (IO) in the United States (US). American Society of Clinical Oncology Annual Meeting; May 31-June 4, 2019; Chicago, IL, USA. Journal of Clinical Oncology 37, no. 15_suppl [Abstract e16025] Published online May 26, 2019.
70. Cowey CL, Taymore E, Boyd M, Aguilar K, Krepler C. Real-world patient profiles and clinical outcomes among patients with BRAF-positive advanced melanoma treated with first-line anti-PD1 monotherapies or BRAF+MEK inhibitor combination therapy in the United States (US) community oncology setting. European Post-Chicago Melanoma / Skin Cancer Meeting, Results and Interpretations of ASCO June 20-21, 2019; Munich, Germany.


75. Sharman J, Shaum Kabadi S, Clark J, Amirian ES, Andorsky DJ. Treatment Patterns and Outcomes of 159 Ibrutinib-Treated MCL Patients in the US: A Retrospective Electronic Medical Record Database and Chart Review Study. International Conference on Pharmacoepidemiology & Therapeutic Risk Management; Aug 24-28, 2019; Philadelphia, PA. ENCORE to the presentation at the 60th ASH Annual Meeting & Exposition, San Diego, CA, USA December 1-4, 2018


treatment following first-line therapy in patients with locally advanced and metastatic urothelial cancer in the community oncology setting in the United States ISPOR EU; Nov 10-14, 2018; Barcelona, Spain. Also ASCO-GU,


84. Doshi G, Bhanegaonkar A, Bharmal M, Phatak H, Aguilar K, Kearney M. SPEAR-Bladder (Study informing treatment Pathway dEcision in bladder cAnceR): first- through third-line time to treatment failure in the US. Poster presented at ASCO; June 1-5, 2018; Chicago, IL.

85. Rifkin RM, Singer D, Baidoo B, Aguilar K, Maires E. Safety of Split First Dosing vs Standard Dosing Administration of Daratumumab among Multiple Myeloma Patients Treated in a US Community Oncology Setting: A Real-World Observational Study. ASH; Dec. 1-4, 2018; San Diego, CA.

86. Sharman J, Kabadi S, Clark J, Amirian ES, Andorsky DJ. Treatment Patterns and Outcomes of 159 Ibrutinib-Treated MCL Patients in the United States: A Retrospective Electronic Medical Record Database and Chart Review Study. ASH; Dec. 1-4, 2018; San Diego, CA.


90. Cartwright T, Parisi M, Espirito JL, Wilson T, Pelletier C, Patel M, Babiker HM. Treatment outcomes with first-line (1L) nab-Paclitaxel + gemcitabine (AG) and FOLFIRINOX (FFX) in metastatic pancreatic adenocarcinoma ASCO; June 2-6, 2017; Chicago, IL. https://ascopubs.org/doi/10.1200/JCO.2017.35.15_suppl.e18147


Treated in the US Community Oncology Setting. ASH Annual Meeting; Dec 9-12, 2017; Atlanta, CA.


99. Sharman J, Black-Shinn J, Clark J, Bitman B. Understanding Ibrutinib Treatment Discontinuation Patterns for Chronic Lymphocytic Leukemia. ASH Annual Meeting; Dec 9-12, 2017; Atlanta, CA.

100. Sharman J, Black-Shinn J, Clark J, Karve S. MCL Treatment Patterns and Outcomes: A Community Oncology Practice Experience. ASH Annual Meeting; Dec 9-12, 2017; Atlanta, CA.


105. Cowey CL. Real-world outcomes of patients with metastatic merkel cell carcinoma treated with second-line or later chemotherapy in a community oncology setting in the United States. ISPOR Annual European Congress Oct. 29 -Nov. 2, 2016; Vienna, Austria.


treatment utilization of palbociclib for metastatic breast cancer (MBC) in a U.S. community
oncology network. ASCO; Jun 3-7, 2016; Chicago, IL.
Treatment patterns and clinical outcomes of patients with metastatic gastroenteropancreatic
neuroendocrine tumors (mGEP-NETs). Gastrointestinal Cancers Symposium; Jan 21-23,
2016; San Francisco, CA.
NJ. Comparative effectiveness of pazopanib and sunitinib as first line therapy for patients
with advanced/metastatic renal cell carcinoma in a US community oncology setting
Genitourinary Cancers Symposium; Jan 7-9, 2016.
112. Huston T, Jiao X, Wilson T, Cisar LA, MacLean EA. Axitinib treatment among patients
with mRCC in a U.S. community oncology setting: A retrospective study of 135 patients.
Genitourinary Cancers Symposium; Jan 7-9, 2016; San Francisco, CA.
113. Patt D, Fonseca E, Yoo B, Wilson T, Goertz HP, Lai C. Real world treatment patterns and
outcomes in HER2 positive MBC patients with brain metastasis in the US community
oncology setting. ASCO Quality Care Symposium; Feb 26-27, 2016; Phoenix, AZ.
dependent patients with diffuse large B-cell lymphoma in a network of community oncology
practices in the United States. ASH; December 3-6, 2016; San Diego, CA.
115. Robert N, Goertz HP, Chopra P, Jiao X, Yoo B, Patt D, Antao V. Clinical characteristics,
treatment patterns, and outcomes for patients with HER2-positive metastatic breast cancer
treated with pertuzumab in the first-line in a real-world setting. European Cancer Congress;
Sept 25-29, 2015; Vienna, Austria.
116. Rifkin RM, Fonseca E, Chen YJ, Fox PS, Browning JE, Cong Z. Carfilzomib dosing
patterns and survival in patients with relapsed and refractory multiple myeloma: an analysis
from US community oncology practices. Annual Meeting of the American Society of
Hematology; Dec. 5-8, 2015; Orlando, FL.
117. Robert N, Goertz HP, Jiao X, Yoo B, Patt D, Antao V. Pertuzumab (P) use in first-line HER2-
positive metastatic breast cancer (mBC) in US community oncology practices: Treatment
patterns and outcomes. San Antonio Breast Cancer Symposium; Dec 8-12, 2015; San
Antonio, TX.
118. Hutson TE, Hackshaw MD, Vogelzang NJ, Bhowmik D, Yap M, Rembert D, Jonasch E.
Outcomes of advanced renal cell carcinoma patients (aRCC) treated with mammalian target
of rapamycin inhibitor (mTORi) therapy following first-line pazopanib (PAZ) in a US
Community Oncology Setting. ESMO; Sept 26-30, 2014; Madrid, Spain.
119. Vogelzang NJ, Hackshaw MD, Hutson TE, Bhowmik D, Yap M, Rembert D, Jonasch E.
Outcomes of advanced renal cell carcinoma patients (aRCC) treated with first-line pazopanib
(PAZ) in a US community oncology setting. ESMO; Sept 26-30, 2014; Madrid, Spain.
120. Cartwright T, Pan I, Wen L, Wadlow RC, Rembert D, Seal B. Treatment patterns and outcomes in metastatic colorectal cancer (mCRC) patients treated in a community oncology setting. ISPOR Annual International Meeting; May 31-Jun 4, 2014; Montreal, QC, Canada.


123. Patt D, Richardson P, Rembert D, Corzo D, Chen C. Treatment of patients (pts) with HER2- metastatic breast cancer (MBC) with nab-paclitaxel (nab-P) in the clinical practice setting—Results of a US Oncology survey. ASCO Annual Meeting; May 30 - June 3, 2014; Chicago, IL.

124. Kumar SK, Engebretson AE, Baudi FK, Lacy MQ, Dispenzieri A, Duh MS, Lafeuille M, Lefebvre P, Cheng W, Dea K, Yap M, Saravanan S, Pan I, Rembert D, Patt D, Niculescu L, Ma E, Quick M, Rajkumar SV. Comparable outcomes and lower total healthcare cost with bortezomib-cyclophosphamide-dexamethasone (VCD) compared to bortezomib-lenalidomide-dexamethasone (VRD) for initial treatment of newly diagnosed multiple myeloma (MM). Association for Value-Based Cancer Care May 6-9, 2014; Los Angeles, CA.

125. Kolibaba KS. Treatment response monitoring in chronic phase CML (CP-CML) patients receiving tyrosine kinase inhibitor (TKI) therapy in US Oncology network. ASCO Annual Meeting; May 31-Jun 4, 2013; Chicago, IL.


129. Chen C, Chen L, Dhanda R, Chung H, Bhowmilk D, Ericson S, DiBella N. Types, frequency, and adherence of molecular tests in chronic myelogenous leukemia at chronic phase (CML-CP) in the U.S. community setting. ASCO Annual Meeting; May 31- Jun 4, 2013; Chicago, IL.


138. Rifkin RM, Chen C, Dhanda R, Rembert D, Ba-Mancini A, Ma E, Zhu Y, Dow E, Niculescu L. Impact of route of bortezomib (B) administration on dose intensity and time to dose reduction in previously untreated patients (pts) With multiple myeloma (MM). Annual Meeting of the American Society of Hematology; Dec 7-10, 2013; New Orleans, LA.

140. Bhor M, Hutson TE, Dhanda R, Liu Z, Vogelzang NJ. Retrospective data study evaluating resource utilization among metastatic renal cell carcinoma patients receiving oral versus intravenous mTOR inhibitors. ASCO Annual Meeting; Jun 1-5, 2012; Chicago, IL.

141. Chen C, Borker R, Dhanda R, Nadler E. Treatment practice patterns and survival among patients with metastatic soft tissue sarcoma (mSTS) in a community setting in the United States. ASCO Annual Meeting; Jun 1-5, 2012; Chicago, IL.


143. Nadler E, Sail K, Chen C, Thompson JA, Kolodziej M. Retrospective observational study: Bevacizumab (B) use and outcomes among metastatic colorectal cancer (mCRC) patients (pts) receiving care in the outpatient community in the United States. Gastrointestinal Cancers Symposium; Jan 19-21, 2012; San Francisco, CA.


147. Chen C, Patt D, Kazzaz DR, Shankleton JA, Forsyth M, Ganesh R. Evaluating utilization characteristics for the Oncotype DX recurrence score in early-stage breast cancer. ASCO Annual Meeting; Jun 3-7, 2011; Chicago, IL.


149. Joshi AD, Forsyth M, Fryefield DC, Lopez W, Chen DM, Ramanan DD. Demographic and treatment characteristics for advanced basal cell carcinoma (aBCC) in an oncology outpatient setting. ASCO Annual Meeting; Jun 3-7, 2011; Chicago, IL.


153. Sail K, Lalla D, Brammer M, Halm M, Patt D. Treatment patterns in patients with HER2-positive early-stage breast cancer (ESBC) receiving adjuvant treatment with a trastuzumab-containing regimen. ASCO Annual Meeting; Jun 3-7, 2011; Chicago, IL.

154. Sharma PP, Sail K, Delea TE, Forsyth M, Halm M, Nagarwala M, Lopez W, Patt D. Patterns of care and patient characteristics in postmenopausal women with HER2+ and hormone receptor-positive (HR+) metastatic breast cancer (MBC). ASCO Annual Meeting; Jun 3-7, 2011; Chicago, IL.


157. Brammer M, Gruschkus S, Lalla D, Doan JF, Forsyth M. HER2 status and trastuzumab use among patients with early breast cancer receiving care within the US Oncology network. ESMO; Oct 8-12, 2010; Milan, Italy.

158. Ravelo A, Nadler E, Yu E, Sing A, Forsyth M, Gruschkus S. Bevacizumab (BV) treatment (Tx) to progression (BTP): outcomes from a US community practice network. ESMO; Oct 8-12, 2010; Milan, Italy.

159. Gruschkus S, Reyes C, Forsyth M, Nadler E, Ravelo A. Economic outcomes among 2nd line non-small cell lung cancer patients in the outpatient community setting. ISPOR Annual European Congress; Nov 6-9, 2010; Prague, Czech Republic.

160. Hoverman JR, Pohl G, Gruschkus S, Marciniak M, Forsyth M, Peltz G. Cost-effectiveness of 1st line chemotherapy regimens in the treatment of NSCLC among patients receiving care in the outpatient community setting. ISPOR; May 15-19, 2010; Atlanta, GA.


164. Gruschkus SK, Doan JF, Chen C, Forsyth M, Lalla D, Shing M. First-line patterns of care and outcomes of HER2-positive breast cancer patients who progressed after receiving adjuvant trastuzumab in the outpatient community setting. ASCO Annual Meeting; Jun 4-8, 2010; Chicago, IL.

165. Neubauer M, Espirito JL, Clayton GC, Patt D. Combination versus sequential chemotherapy for metastatic breast cancer: An evaluation of outcomes from a community oncology network. ASCO Annual Meeting; Jun 4-8, 2010; Chicago, IL.


171. Gruschkus SK, Shankleton JA, Brammer M, Forsyth M, Lalla D. First-line trastuzumab utilization: Patterns of care and progression in the community setting. ASCO Annual Meeting; May 29-Jun 2, 2009; Orlando, FL.